A carregar...
Mineral and Electrolyte Disorders With SGLT2i Therapy
The newly developed sodium‐glucose cotransporter 2 inhibitors (SGLT2is) effectively modulate glucose metabolism in diabetes. Although clinical data suggest that SGLT2is (empagliflozin, dapagliflozin, ertugliflozin, canagliflozin, ipragliflozin) are safe and protect against renal and cardiovascular e...
Na minha lista:
| Publicado no: | JBMR Plus |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6874177/ https://ncbi.nlm.nih.gov/pubmed/31768494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbm4.10242 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|